UPC — Universe Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $87.73m
- $74.70m
- $32.31m
- 82
- 29
- 77
- 66
2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 20-F | 20-F | 20-F |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 33.2 | 30.7 | 48 | 40.1 | 32.3 |
Cost of Revenue | |||||
Gross Profit | 13.7 | 14.1 | 25.3 | 21.9 | 10.3 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 23.5 | 20.5 | 34.4 | 47.6 | 35.8 |
Operating Profit | 9.75 | 10.3 | 13.6 | -7.44 | -3.53 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 9.65 | 10.1 | 13.7 | -7.98 | -3.85 |
Provision for Income Taxes | |||||
Net Income After Taxes | 7.55 | 7.56 | 11.3 | -8.74 | -6.16 |
Net Income Before Extraordinary Items | |||||
Net Income | 7.55 | 7.56 | 11.3 | -8.74 | -6.16 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 7.55 | 7.56 | 11.3 | -8.74 | -6.16 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 2.22 | 2.16 | 3.58 | -2.41 | -1.7 |
Dividends per Share |